浩欧博(688656)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688656 浩欧博

已收盘 01-10 15:00:00

{"stockData":{"symbol":"688656","market":"SH","secType":"STK","nameCN":"浩欧博","latestPrice":85.5,"timestamp":1736492400000,"preClose":90.98,"halted":0,"volume":845203,"delay":0,"changeRate":-0.0602,"floatShares":63058300,"shares":63058300,"eps":0.5592,"marketStatus":"已收盘","change":-5.48,"latestTime":"01-10 15:00:00","open":89.28,"high":91.37,"low":85.12,"amount":74128500,"amplitude":0.0687,"askPrice":85.86,"askSize":2,"bidPrice":85.5,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.5592,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1736731800000},"marketStatusCode":5,"adr":0,"adjPreClose":90.98,"symbolType":"stock_kcb","openAndCloseTimeList":[[1736472600000,1736479800000],[1736485200000,1736492400000]],"highLimit":100.08,"lowLimit":81.88,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":63058328,"isCdr":false,"pbRate":6.69,"roa":"--","peRate":152.896996,"roe":"3.27%","epsLYR":0.75,"committee":-0.04,"marketValue":5391000000,"turnoverRate":0.0134,"status":1,"afterMarket":{"amount":0,"volume":0,"close":85.5,"buyVolume":0,"sellVolume":0,"time":1736494438029,"indexStatus":"已收盘 01-10 15:30:00","preClose":90.98},"floatMarketCap":5391000000},"requestUrl":"/m/hq/s/688656","defaultTab":"news","newsList":[{"id":"2502890758","title":"浩欧博大跌 获1家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2502890758","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502890758?lang=zh_cn&edition=full","pubTime":"2025-01-10 14:13","pubTimestamp":1736489604,"startTime":"0","endTime":"0","summary":"01月10日，浩欧博股价大幅下跌，截至14点13分，浩欧博下跌5.11%，报86.33元/股，失守90元整数关口，成交5097万元，换手率0.91%。此外，数据统计显示，近半年内1家券商给予买入建议。资金动向截止发稿，浩欧博获得主力净流出1016万元，其中超大单流出181万元，大单流出833万元。最新财报显示，今年三季报，浩欧博实现营业收入3.07亿元，同比增长2.29%，净利润为2,656.30万元，同比减少31.24%，基本每股收益为0.42元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110141338a21c7efb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110141338a21c7efb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2502606772","title":"浩欧博：全资子公司获得2项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2502606772","media":"格隆汇资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502606772?lang=zh_cn&edition=full","pubTime":"2025-01-09 16:02","pubTimestamp":1736409770,"startTime":"0","endTime":"0","summary":"格隆汇1月9日丨浩欧博公布，公司全资子公司湖南浩欧博生物医药有限公司于近日获得湖南省药品监督管理局核准签发的2项医疗器械注册证；上述医疗器械注册证的取得，进一步丰富了公司化学发光平台检测菜单，有助于提升公司市场综合竞争力，对公司及子公司的可持续性发展将产生积极影响和促进作用。抗磷脂酶A2受体抗体IgG检测试剂盒，本试剂盒用于体外定量检测人血清样本中抗磷脂酶A2受体抗体的含量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010916025895fdbb08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010916025895fdbb08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688656","159883","BK0239"],"gpt_icon":0},{"id":"2502061049","title":"浩欧博(688656.SH)子公司获得2项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2502061049","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502061049?lang=zh_cn&edition=full","pubTime":"2025-01-09 15:43","pubTimestamp":1736408637,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浩欧博(688656.SH)发布公告，公司全资子公司湖南浩欧博生物医药有限公司于近日获得湖南省药品监督管理局核准签发的2项医疗器械注册证。涉及产品：“自身免疫性肌炎抗体谱1检测试剂盒(磁微粒化学发光法)”、“抗磷脂酶A2受体抗体IgG检测试剂盒(磁微粒化学发光法)”。上述医疗器械注册证的取得，进一步丰富了公司化学发光平台检测菜单，有助于提升公司市场综合竞争力，对公司及子公司的可持续性发展将产生积极影响和促进作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1235433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","688656","159883","BK1222","BK1100","BK1583","BK1574","09996","BK0239"],"gpt_icon":0},{"id":"2502721032","title":"浩欧博股价大涨 券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2502721032","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502721032?lang=zh_cn&edition=full","pubTime":"2025-01-09 09:38","pubTimestamp":1736386731,"startTime":"0","endTime":"0","summary":"01月09日，浩欧博股价大幅上涨，截至09点38分，浩欧博上涨5.07%，报92.99元/股，突破90元整数关口，成交1246万元，换手率0.22%。资金动向截止发稿，浩欧博获得主力净流入347万元，其中超大单流入130万元，大单流入216万元。主营业务及业绩浩欧博公司主营业务为从事体外诊断试剂的研发、生产和销售。最新财报显示，今年三季报，浩欧博实现营业收入3.07亿元，同比增长2.29%，净利润为2,656.30万元，同比减少31.24%，基本每股收益为0.42元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109093856a21ae67f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109093856a21ae67f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2500319682","title":"国办：审评审批资源向临床急需重点创新药和医疗器械倾斜","url":"https://stock-news.laohu8.com/highlight/detail?id=2500319682","media":"北京商报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500319682?lang=zh_cn&edition=full","pubTime":"2025-01-03 18:49","pubTimestamp":1735901344,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 王寅浩）1月3日，国务院办公厅发布《关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》（以下简称《意见》）。《意见》提出，要完善审评审批机制全力支持重大创新。按照“提前介入、一企一策、全程指导、研审联动”要求，审评审批资源更多向临床急需的重点创新药和医疗器械倾斜，在临床试验、注册申报、核查检验、审评审批等全过程加强沟通交流，提供个性化指导。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010318490695f7a94d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010318490695f7a94d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688575","603987","688131","688520","BK0251","688338","600763","159883","603733","688767","603590","603205","600080","688578","688656","601089","688621","159992","688607","603087","603583","603301","688193","600829","688687","688161","688799","688389","688212","688013","688580","688710","688176","688289","600998","605369","688358","688075","688050","688192","688166","688278","688314","688302","600135","688067","603976","688331","688356","688468","BK0239","688606","688382"],"gpt_icon":0},{"id":"2500886118","title":"国办：研究组建医用机器人等前沿医疗器械标准化技术组织","url":"https://stock-news.laohu8.com/highlight/detail?id=2500886118","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500886118?lang=zh_cn&edition=full","pubTime":"2025-01-03 17:23","pubTimestamp":1735896220,"startTime":"0","endTime":"0","summary":"中新经纬1月3日电 国务院办公厅发文提出，优化医疗器械标准体系，研究组建人工智能、医用机器人等前沿医疗器械标准化技术组织。加强中医医疗器械标准制定。在提高药品医疗器械审评审批质效方面，《意见》要求，加强药品医疗器械注册申报前置指导，加快临床急需药品医疗器械审批上市，优化临床试验审评审批机制，优化药品补充申请审评审批，优化药品医疗器械注册检验，加快罕见病用药品医疗器械审评审批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103204811985a29a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103204811985a29a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688656","BK0130","688580","BK0073","600829","688067","BK0089","300024","BK0259","688468","603987","600135","688338","688617","BK0005","BK0239","688050","688289","688075","688575","BK0251","603976","600998","688358","603087","688013","BK0188","603386","605369","BK0196","BK0122","159883","603205","159526","688193","BK0061","603301","688314","688606","688767","688198","688212","688389","600763","603733","BK0028","688161"],"gpt_icon":0},{"id":"2500391857","title":"浩欧博大跌 券商曾建议买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2500391857","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500391857?lang=zh_cn&edition=full","pubTime":"2025-01-02 14:38","pubTimestamp":1735799895,"startTime":"0","endTime":"0","summary":"01月02日，浩欧博股价大幅下跌，截至14点38分，浩欧博下跌5.20%，报90.53元/股，创近1个月新低，成交5152万元，换手率0.87%。资金动向截止发稿，浩欧博获得主力净流出314万元，其中超大单流出367万元，大单流入54万元。融资融券方面，浩欧博12月31日获得融资净买入110万元，当日该股融资余额为8626万元，当较前一日增加1.30%，实现3连增。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010214384595f61e55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010214384595f61e55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2495694597","title":"浩欧博收盘下跌1.45%，滚动市盈率170.79倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2495694597","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495694597?lang=zh_cn&edition=full","pubTime":"2024-12-31 20:26","pubTimestamp":1735647965,"startTime":"0","endTime":"0","summary":"12月31日，浩欧博今日收盘95.5元，下跌1.45%，滚动市盈率PE达到170.79倍。从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.73倍，行业中值31.98倍，浩欧博排名第112位。截至2024年三季报，共有6家机构持仓浩欧博，其中其他6家，合计持股数4705.35万股，持股市值13.48亿元。最新一期业绩显示，2024年三季报，公司实现营业收入3.07亿元，同比2.29%；净利润2656.30万元，同比-31.24%，销售毛利率64.35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231202910985672a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231202910985672a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2495844456","title":"浩欧博上涨5.13%，报101.88元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2495844456","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495844456?lang=zh_cn&edition=full","pubTime":"2024-12-31 09:34","pubTimestamp":1735608892,"startTime":"0","endTime":"0","summary":"12月31日，浩欧博盘中上涨5.13%，截至09:34，报101.88元/股，成交1142.38万元，换手率0.18%，总市值64.24亿元。截至9月30日，浩欧博股东户数2621，人均流通股2.41万股。2024年1月-9月，浩欧博实现营业收入3.07亿元，同比增长2.29%；归属净利润2656.3万元，同比减少31.24%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412310937039855b74a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412310937039855b74a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2495449684","title":"浩欧博突破百元 券商看多","url":"https://stock-news.laohu8.com/highlight/detail?id=2495449684","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495449684?lang=zh_cn&edition=full","pubTime":"2024-12-31 09:34","pubTimestamp":1735608890,"startTime":"0","endTime":"0","summary":"12月31日，浩欧博股价大幅上涨，截至09点34分，浩欧博上涨5.13%，报101.88元/股，突破100元整数关口，成交1142万元，换手率0.18%，振幅5.13%。融资融券方面，浩欧博12月27日获得融资净买入27万元，当日该股融资余额为8396万元，当较前一日增加0.33%。最新财报显示，今年三季报，浩欧博实现营业收入3.07亿元，同比增长2.29%，净利润为2,656.30万元，同比减少31.24%，基本每股收益为0.42元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231093455a20fbd79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231093455a20fbd79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2495516530","title":"与药明生物合作全球首创新药，中生制药转型加速跑，2个月前刚收购浩欧博","url":"https://stock-news.laohu8.com/highlight/detail?id=2495516530","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495516530?lang=zh_cn&edition=full","pubTime":"2024-12-30 17:36","pubTimestamp":1735551400,"startTime":"0","endTime":"0","summary":"就双方合作的具体情况，截至发稿，时代财经尚未获得中生制药及药明生物的回复。今年以来，中生制药对外合作的步伐进一步加速。更早以前，今年10月底，中生制药收购了一家科创板上市企业。收购完成后，中生制药通过全资子公司辉煌润康和控股子公司双润正安，将持有浩欧博55%股权，成为其新的实际控制人。交易完成后，浩欧博将成为中生制药旗下第一家A股上市公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412301738439854d2a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412301738439854d2a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","688656","LU0307460666.USD","IE00B0JY6N72.USD","LU1688375341.USD","LU0039217434.USD","LU1242518931.SGD","LU0181495838.USD","LU1720050803.USD","LU0140636845.USD","LU1242518857.USD","BK1161","LU0819121731.USD","BK1521","LU0052750758.USD","LU1880383366.USD","LU0708995583.HKD","LU0979878070.USD","LU0359202008.SGD","BK1589","LU0856984785.SGD","LU0359201612.USD","LU0320764599.SGD","BK1191","LU0588546209.SGD","LU0516422366.SGD","BK1574","LU0456846285.SGD","BK1141","LU0572944931.SGD","SG9999002463.SGD","LU0417516738.SGD","LU0417516902.SGD","LU0456827905.SGD","LU0043850808.USD","BK1576","BK1610","LU0823426308.USD","LU0823426480.USD","LU0348825331.USD","SG9999002562.SGD","01477","LU0051755006.USD","LU2039709279.SGD","LU0348735423.USD","LU0516423174.USD","02269","LU0516422952.EUR","LU0327786744.USD","LU0326950275.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2494952350","title":"浩欧博（688656）12月27日主力资金净买入44.18万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2494952350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494952350?lang=zh_cn&edition=full","pubTime":"2024-12-28 08:26","pubTimestamp":1735345608,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月27日收盘，浩欧博报收于97.9元，下跌1.68%，换手率1.61%，成交量1.02万手，成交额1.01亿元。近5日资金流向一览见下表：浩欧博融资融券信息显示，融资方面，当日融资买入552.98万元，融资偿还525.2万元，融资净买入27.79万元。浩欧博主营业务：从事体外诊断试剂的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122800008563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2494395812","title":"【机构调研记录】申万菱信基金调研浩欧博","url":"https://stock-news.laohu8.com/highlight/detail?id=2494395812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494395812?lang=zh_cn&edition=full","pubTime":"2024-12-27 08:02","pubTimestamp":1735257768,"startTime":"0","endTime":"0","summary":"申万菱信基金成立于2004年，截至目前，资产管理规模911.25亿元，排名65/208；资产管理规模796.54亿元，排名55/208；管理公募基金数153只，排名46/208；旗下公募基金经理29人，排名43/208。旗下最近一年表现最佳的公募基金产品为申万菱信中证沪港深数字经济主题指数型发起式A，最新单位净值为1.2，近一年增长41.54%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122700006060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2494855341","title":"浩欧博：12月25日组织现场参观活动，上海东方证券资产管理有限公司、东吴证券股份有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2494855341","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494855341?lang=zh_cn&edition=full","pubTime":"2024-12-26 18:32","pubTimestamp":1735209150,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年12月26日浩欧博发布公告称公司于2024年12月25日组织现场参观活动，上海东方证券资产管理有限公司、东吴证券股份有限公司、富国基金管理有限公司、中银基金管理有限公司、摩根基金管理(中国)有限公司、申万菱信基金管理有限公司参与。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122600028224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1229","BK1147","BK0009","BK1258","BK0188","BK0239","BK0183","688656","BK0028","BK1542","BK1564","BK1583","BK0276","09983","600958","03958","BK0012","601555"],"gpt_icon":0},{"id":"2494606058","title":"浩欧博大跌 券商曾建议买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2494606058","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494606058?lang=zh_cn&edition=full","pubTime":"2024-12-25 10:03","pubTimestamp":1735092222,"startTime":"0","endTime":"0","summary":"12月25日，浩欧博股价大幅下跌，截至10点03分，浩欧博下跌5.27%，报95.01元/股，创近1个月新低，成交4174万元，换手率0.68%。资金动向截止发稿，浩欧博获得主力净流入59万元，其中超大单流入7万元，大单流入51万元。主营业务及业绩浩欧博公司主营业务为从事体外诊断试剂的研发、生产和销售。最新财报显示，今年三季报，浩欧博实现营业收入3.07亿元，同比增长2.29%，净利润为2,656.30万元，同比减少31.24%，基本每股收益为0.42元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122510142195ebc228&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122510142195ebc228&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2493388086","title":"浩欧博收盘上涨3.07%，滚动市盈率179.37倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2493388086","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493388086?lang=zh_cn&edition=full","pubTime":"2024-12-24 20:44","pubTimestamp":1735044273,"startTime":"0","endTime":"0","summary":"12月24日，浩欧博今日收盘100.3元，上涨3.07%，滚动市盈率PE达到179.37倍。从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.82倍，行业中值33.23倍，浩欧博排名第108位。消息面上，浩欧博11月22日接待平安证券股份有限公司等13家机构调研，上市公司接待人员包括董事会秘书谢爱香。江苏浩欧博生物医药股份有限公司是专业从事体外诊断试剂的研发、生产和销售的高新技术企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224204803984d690f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224204803984d690f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2493775999","title":"浩欧博股价涨5% 创新器械获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2493775999","media":"智选洞察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493775999?lang=zh_cn&edition=full","pubTime":"2024-12-24 14:44","pubTimestamp":1735022680,"startTime":"0","endTime":"0","summary":"12月24日，浩欧博股价大幅上涨，截至14点44分，浩欧博上涨5.23%，报102.40元/股，突破100元整数关口，成交1.30亿元，换手率2.08%，振幅6.78%。资金动向截止发稿，浩欧博获得主力净流入766万元，其中超大单流入362万元，大单流入404万元。主营业务及业绩浩欧博公司主营业务为从事体外诊断试剂的研发、生产和销售。最新财报显示，今年三季报，浩欧博实现营业收入3.07亿元，同比增长2.29%，净利润为2,656.30万元，同比减少31.24%，基本每股收益为0.42元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224144500984d4ff7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224144500984d4ff7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688656"],"gpt_icon":0},{"id":"2493214254","title":"A股IVD创始人变现11.13个亿！离场","url":"https://stock-news.laohu8.com/highlight/detail?id=2493214254","media":"医疗器械创新网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493214254?lang=zh_cn&edition=full","pubTime":"2024-12-22 17:15","pubTimestamp":1734858955,"startTime":"0","endTime":"0","summary":"2024 年 12 月 12 日，前述浩欧博股份转让已完成过户登记。本次交易完成后，浩欧博将成为中国生物制药在 A 股证券市场控股的第一家上市子公司。本次要约收购目的为收购人及其一致行动人进一步提升对上市公司的持股比例，增强上市公司控制权稳定性。本次要约收购类型为主动要约，并非履行法定要约收购义务。也就是说，浩欧博创始人团队除之前获得协议转让的6.3亿元之外，通过本次要约收购预计还可获得4.83亿元，共获11.13亿元，体面离场！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222171749a201d925&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222171749a201d925&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159982","688656","399300","BK0239"],"gpt_icon":0},{"id":"2493047884","title":"95后买走IVD上市公司，创始人赚了11.13亿！","url":"https://stock-news.laohu8.com/highlight/detail?id=2493047884","media":"MedWorld器械世界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493047884?lang=zh_cn&edition=full","pubTime":"2024-12-21 08:30","pubTimestamp":1734741057,"startTime":"0","endTime":"0","summary":"若收购完成后上市公司股权分布不具备上市条件，收购人及其一致行动人将协调解决，以维持上市地位，但提请投资者关注相关风险。本次要约收购类型为主动要约，不以终止上市公司上市地位为目的。综合来看，浩欧博创始人团队通过本次要约收购预计还可获得4.83亿元，此前收购已经获得6.3亿元，合计约11.13亿元，手里目前还剩余少量股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221084903ab885890&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221084903ab885890&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688656","BK0239"],"gpt_icon":0},{"id":"2492436154","title":"浩欧博收盘下跌0.94%，滚动市盈率181.11倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2492436154","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492436154?lang=zh_cn&edition=full","pubTime":"2024-12-20 21:08","pubTimestamp":1734700098,"startTime":"0","endTime":"0","summary":"12月20日，浩欧博今日收盘101.27元，下跌0.94%，滚动市盈率PE达到181.11倍。从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.61倍，行业中值33.52倍，浩欧博排名第108位。消息面上，浩欧博11月22日接待平安证券股份有限公司等13家机构调研，上市公司接待人员包括董事会秘书谢爱香。最新一期业绩显示，2024年三季报，公司实现营业收入3.07亿元，同比2.29%；净利润2656.30万元，同比-31.24%，销售毛利率64.35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220211212ab87350d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220211212ab87350d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688656"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-01-13","address":"江苏省苏州市吴中区苏州工业园区星湖街218号生物纳米园C6栋101","stockEarnings":[{"period":"1week","weight":-0.035},{"period":"1month","weight":-0.2234},{"period":"3month","weight":2.1561},{"period":"6month","weight":2.4559},{"period":"1year","weight":1.5764},{"period":"ytd","weight":-0.1047}],"companyName":"江苏浩欧博生物医药股份有限公司","boardCode":"AI0027","perCapita":"24058股","boardName":"医药制造业","registeredCapital":"6305万元","compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0769},{"period":"3month","weight":-0.0153},{"period":"6month","weight":0.0664},{"period":"1year","weight":0.0976},{"period":"ytd","weight":-0.0547}],"survey":"　　江苏浩欧博生物医药股份有限公司是专业从事体外诊断试剂的研发、生产和销售的高新技术企业。公司的产品主要用于血液中相关抗体检测，有过敏和自免两大产品系列。浩欧博已进入以北京协和、上海仁济、中国医大二院、华西二院等为代表的多家旗帜性医院。与金域医学、迈瑞医疗等国内龙头企业建立战略合作关系。","serverTime":1736580470588,"listedPrice":35.26,"stockholders":"2621人(较上一季度减少4.79%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"浩欧博(688656)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供浩欧博(688656)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"浩欧博,688656,浩欧博股票,浩欧博股票老虎,浩欧博股票老虎国际,浩欧博行情,浩欧博股票行情,浩欧博股价,浩欧博股市,浩欧博股票价格,浩欧博股票交易,浩欧博股票购买,浩欧博股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"浩欧博(688656)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供浩欧博(688656)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}